From The Editor | By Ed Miseta, chief editor, Clinical Leader
A preferred provider and/or a strategic provider is a vendor company, often a CRO or other specialty service provider, that has achieved priority status in the awarding of contracts by pharma/biotech companies. With the growing complexity of clinical research, the preferred provider is gaining popularity with many companies. Clinical Leader's chief editor, Ed Miseta, talks with Jennifer Johnson of UCB in this Q&A.
The functional service provider (FSP) model has experienced accelerated adoption and an increase in popularity in recent years, due, in part, to the flexibility and control it affords sponsors when compared to full-service offerings (FSOs).
What steps are needed to hire the best and brightest at CROs? Get a better understanding of the challenges facing today’s recruiters and explore these seven tips for hiring and retaining top CRO talent.
Karyopharm had multiple trials in their pipeline, all in various phases of development, and all on tight timelines. Find out how they outsourced data aggregation, cleaning, metric generation, and the manual development of SAE.
ISR consistently seeks to demystify the mystical, and there’s plenty of mystery regarding clinical trial logistics. How do sponsors select a provider? Which activities do they outsource the most? Where are these questions heading?
To accommodate changing requirements and encourage the adoption of new technology, India’s Ministry of Health and Family Welfare released a draft bill in July 2022 to replace the existing Drugs and Cosmetics Act 1940. What are the major areas of change and how much of an impact will there be?
Do you ever feel as if your trial could be at risk? What if you don’t catch missed adverse events or something more important? Find out the ways you can combat risk in your clinical trial.
To better understand what sIRB review requirements mean for sites and sponsors, it’s important to first understand what a single IRB is and how it works. Gain insight into a single IRB review in the U.S.
EU Annex 11 lays out the European Union’s regulations for using computerized systems during clinical trials. Explore how sponsors and sites, who want their new medical treatment approved in the EU, must follow Annex 11.
Discover a strategic regulatory plan and leverage the right pathways to drive faster and more efficient drug development.
Choose Your Own Adventure
You're receiving the Thursday edition of the Clinical Leader newsletter, focusing on Outsourcing Models and Regulatory & Compliance. To make changes to your newsletter selections, update your topic preferences.
Clinical Data Management & Analytics | Trial Monitoring (Friday)
Learn more about our personalized newsletters here.
This newsletter is being sent to {{lead.Email Address}}. If the topics covered in it are no longer of interest to you, you can change your topic preferences on your profile page. To cancel your subscription to all Clinical Leader newsletters, please unsubscribe.
This website uses cookies to ensure you get the best experience on our website. Learn more